US Bancorp’s Jade Biosciences JBIO Stock Holding History

US Bancorp’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18K	Buy	53 +38	+253%	+$792	﹤0.01%	3951
2026 Q1	$211	Buy	+15	New	+$217	﹤0.01%	4093

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

US Bancorp's JBIO Position: Q2 2026 in Review

US Bancorp increased its Jade Biosciences (JBIO) stake by 253% in Q2 2026, buying an estimated $792 and bringing the position to 53 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #3951.

US Bancorp first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

US Bancorp held 53 shares of Jade Biosciences worth $1.18K as of Q2 2026.
US Bancorp bought 38 Jade Biosciences shares in Q2 2026, an estimated $792.
Jade Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3951 holding.
US Bancorp first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.